Bio & Pharma
JW Pharma to participate in S.Korea’s new drug project
The company will receive two-year KDDF funding for non-clinical research of its hair loss treatment JW0061
By Aug 28, 2023 (Gmt+09:00)
1
Min read
Most Read
Macquarie eyes its 1st Korean data center valued around $722 mn
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![JW Pharma to participate in S.Korea’s new drug project](https://www.kedglobal.com/data/ked/image/2023/08/28/ked202308280013.647x.0.jpg)
South Korea's JW Pharmaceutical announced on Monday that its experimental hair loss drug, JW0061, has been selected for a two-year funding program by the Korea Drug Development Fund (KDDF), the country's premier public funder of pharmaceutical research and development.
JW0061, described as a groundbreaking drug candidate, aims to tackle hair loss by targeting the Wnt signaling pathway, a critical mechanism involved in skin and hair follicle development.
"The drug uniquely activates a new target, GFRA1, which is unrelated to male hormones," a company source said. "As a result, JW0061 is expected to be safe and effective for both male and female patients experiencing hair loss."
The funding boost from KDDF comes as JW Pharmaceutical is actively conducting toxicity assessments for the drug with the goal of launching clinical trials next year.
The company also revealed ongoing efforts to optimize a transdermal (patch-type) formulation, offering patients a more convenient treatment application.
The KDDF is a national consortium backed by three South Korean government ministries and is recognized as the largest public source of drug R&D funding in the country.
This funding initiative will cover non-clinical trial costs for JW0061 over the next two years.
Write to Hyun-Ah Oh at 5hyun@hankyung.com
More to Read
-
Bio & PharmaJW Pharma gets OK for phase 3 clinical trials of URC102 in Taiwan
Aug 18, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaJW Pharma unveils S.Korea's first homegrown hybrid incubator
Jun 29, 2023 (Gmt+09:00)
1 Min read -
-
Bio & PharmaJW Pharma receives 1st overseas patent for its hair loss treatment
Mar 27, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaJW Pharma to put AI into new drug ingredient development
Jan 30, 2023 (Gmt+09:00)
1 Min read
Comment 0
LOG IN